2014
DOI: 10.5530/jyp.2015.1.2
|View full text |Cite
|
Sign up to set email alerts
|

Saroglitazar, a novel cardiometabolic agent for diabetic dyslipidemia - A Review

Abstract: Diabetes mellitus is a worldwide prevalent chronic disease with a significant disease burden. The associated dyslipidemia adds to the lethality of type 2 diabetes mellitus and requires newer and better treatment strategies. Peroxisome proliferator activated receptor (PPAR) α and γ agonists are approved hypolipidemic and anti-diabetic agents respectively and combining them together provides a dual benefit in type 2 diabetes mellitus associated with dyslipidemia. This novel class of dual PPAR agonists are termed… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
5
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(5 citation statements)
references
References 21 publications
0
5
0
Order By: Relevance
“…7 The substance was approved in June 2013 for clinical use in India. 53 Saroglitazar has never been associated with cardiovascular complications, although its product information contains a precautionary statement for its use in patients with T2D and congestive heart failure. These findings combined with those from older studies for other dual PPARα/γ agonists presented the high efficiency of dual PPARα/γ agonists against hyperglycemia and hyperlipidemia.…”
Section: Dual Pparα/γ Agonistsmentioning
confidence: 99%
“…7 The substance was approved in June 2013 for clinical use in India. 53 Saroglitazar has never been associated with cardiovascular complications, although its product information contains a precautionary statement for its use in patients with T2D and congestive heart failure. These findings combined with those from older studies for other dual PPARα/γ agonists presented the high efficiency of dual PPARα/γ agonists against hyperglycemia and hyperlipidemia.…”
Section: Dual Pparα/γ Agonistsmentioning
confidence: 99%
“…Indeed, dual-PPAR α / γ agonists have been in development under great interest. Although there are none approved in the US, saroglitazar was approved in June 2013 for clinical use in India [ 224 ]. Saroglitazar has a higher affinity for PPAR α than PPAR γ .…”
Section: Ppar Agonists On Cardiac Function In the Clinical Settingmentioning
confidence: 99%
“…Saroglitazar [(S)-a-ethoxy-4-{2-[2-methyl-5-(4-methylthio) phenyl)]-1H-pyrrol-1-yl]-ethoxy)-benzenepropanoic acid magnesium salt] is a novel PPAR α/γ agonist synthesized in India by Zydus Cadila (trade name, Lipaglycn), and is approved by the Drug Controller General of India (DCGI) for the treatment of diabetic dyslipidemia and hypertriglyceridemia [14]. Saroglitazar is not associated with weight gain and edema [13], and thus it is considered a safer medication, with fewer adverse effects such as gastritis, asthenia, and pyrexia [15]. There is a lack of pooled evidence on the safety and efficacy of saroglitazar for the treatment of dyslipidemia.…”
Section: Introductionmentioning
confidence: 99%